HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
申请人:Merck & Co., Inc.
公开号:EP1434773A2
公开(公告)日:2004-07-07
EP1434773A4
申请人:——
公开号:EP1434773A4
公开(公告)日:2005-01-12
US7253190B2
申请人:——
公开号:US7253190B2
公开(公告)日:2007-08-07
[EN] HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5<br/>[FR] COMPOSES DE TETRAZOLE SUBSTITUES PAR HETEROARYLE, MODULATEURS DU RECEPTEUR-5 METABOTROPIQUE DU GLUTAMATE
申请人:MERCK & CO INC
公开号:WO2003029210A2
公开(公告)日:2003-04-10
Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
[EN] TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE<br/>[FR] TRAITEMENT DE L'OBESITE ET D'AUTRES TROUBLES ASSOCIES A UNE CONSOMMATION ALIMENTAIRE EXCESSIVE
申请人:MERCK & CO INC
公开号:WO2004030637A2
公开(公告)日:2004-04-15
Modulators of metabotropic glutamate receptor-5 (mGluR5) are useful in treating disorders associated with excessive food intake, including obesity and obesity-related disorders. In particular, mGluR5 antagonists of structural formulae IA-IF are useful in treating these conditions, either as single agents or in combination with other compounds useful for treating obesity.